PVPhilippe Vayer

Philippe Vayer

*This is an algorithmically generated author record based on publicly available information.

Philippe Vayer has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • UPLC–MS retention time prediction: a machine learning approach to metabolite identification in untargeted profiling

    by Arnaud M. Wolfer, Sylvain Lozano, Thierry Umbdenstock, Vincent Croixmarie, Alban Arrault, Philippe Vayer


  • New QSAR Models for Human Cytochromes P450, 1A2, 2D6 and 3A4 Implicated in the Metabolism of Drugs. Relevance of Dataset on Model Development.

    by Juan Martinez-Sanz, Pascal Bonnet, Sylvain Lozano, Alban Arrault, Luc Morin-Allory, Philippe Vayer


  • In Silico Prediction of Aqueous Solubility: A Multimodel Protocol Based on Chemical Similarity

    by Florent Chevillard, David Lagorce, Christelle Reynès, Bruno O. Villoutreix, Philippe Vayer, Maria A. Miteva

    Aqueous solubility is one of the most important ADMET properties to assess and to optimize during the drug discovery process. At present, accurate prediction of solubility remains very challenging and there is an important need of independent benchmarking of the existing in silico models such as to suggest solutions for their improvement. In this study, we developed a new protocol for improved solubility prediction by combining several existing models available in commercial or free software packages. We first performed an evaluation of ten in silico models for aqueous solubility prediction on several data sets in order to assess the reliability of the methods, and we proposed a new diverse data set of 150 molecules as relevant test set, SolDiv150. We developed a random forest protocol to evaluate the performance of different fingerprints for aqueous solubility prediction based on molecular structure similarity. Our protocol, called a “multimodel protocol”, allows selecting the most accurate model for a compound of interest among the employed models or software packages, achieving r2 of 0.84 when applied to SolDiv150. We also found that all models assessed here performed better on druglike molecules than on real drugs, thus additional improvement is needed in this direction. Overall, our approach enlarges the applicability domain as demonstrated by the more accurate results for solubility prediction obtained using our protocol in comparison to using individual models.


  • QSAR Modelling of CYP3A4 Inhibition as a Screening Tool in the Context of Drug-Drug Interaction Studies

    by Véronique Hamon, Dragos Horvath, Cédric Gaudin, Julie Desrivot, Céline Junges, Alban Arrault, Marc Bertrand, Philippe Vayer

    Drugdrug interaction potential (DDI), especially cytochrome P450 (CYP) 3A4 inhibition potential, is one of the most important parameters to be optimized before preclinical and clinical pharmaceutical development as regard to the number of marketed drug metabolized mainly by this CYP and potentially co-administered with the future drug. The present study aims to develop in silico models for CYP3A4 inhibition prediction to help medicinal chemists during the discovery phase and even before the synthesis of new chemical entities (NCEs), focusing on NCEs devoid of any inhibitory potential toward this CYP. In order to find a relevant relationship between CYP3A4 inhibition and chemical features of the screened compounds, we applied a genetic-algorithm-based QSAR exploratory tool SQS (Stochastic QSAR Sampler) in combination with different description approaches comprising alignment-independent Volsurf descriptors, ISIDA fragments and Topological Fuzzy Pharmacophore Triplets. The experimental data used to build models were extracted from an in-house database. We derived a model with good prediction ability that was confirmed on both newly synthesized compound and public dataset retrieved from Pubchem database. This model is a promising efficient tool for filtering out potentially problematic compounds.


  • Open Access

    Mining collections of compounds with Screening Assistant 2

    by Vincent Le Guilloux, Alban Arrault, Lionel Colliandre, Stéphane Bourg, Philippe Vayer, Luc Morin-Allory

    High-throughput screening assays have become the starting point of many drug discovery programs for large pharmaceutical companies as well as academic organisations. Despite the increasing throughput of screening technologies, the almost infinite chemical space remains out of reach, calling for tools dedicated to the analysis and selection of the compound collections intended to be screened.


  • Apports de la chémo-informatique dans la recherche et l’optimisation des molécules d’intérêt thérapeutique

    by Philippe Vayer, Alban Arrault, Brigitte Lesur, Marc Bertrand, Bernard Walther

    Successful identification of new chemical entities with drug-like properties in pharmaceutical and academic research groups involves an early screen and the use of a large number of public and proprietary chemical libraries. Before applying high-throughput experimental screening approaches, virtual screening strategies have been put in place in order to sort and filter this massive amount of compounds and data available at these very early stages. Chemoinformatic tools have a crucial role in this selection process and enable therapeutic chemists to focus very early on promising candidates. Virtual screening has conventionally been based either on models of the target or the ligand (molecule), but today these models include biopharmaceutical filters addressing right from the start of the project the ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties of the molecules. Above all, chemoinformatic tools help chemists understand better the chemical diversity they can work with, especially when comparing chemical libraries. This paper will focus on exemples of the day-to-day use of chemoinformatics in screening programs. A large part will be dedicated to new tools (chemographic and pharmacographic approaches) being developed for the representation and analysis of chemical diversity, but also for combining chemical and biological information to expedite research programs.